Korea delivered two breakthrough reimbursement decisions, opening transformative access to Ultomiris for refractory generalized myasthenia gravis and elevating Jemperli to first-line status in dMMR/MSI-H endometrial cancer.
Reimbursement Momentum Favours SKYRIZI, Tagrisso and Cosentyx Friday brought major reimbursement shifts in Canada and Korea, recalibrating near-term access in inflammatory bowel disease, EGFR-mutated lung cancer and hidradenitis suppurativa. AbbVie secured a major win in Canada as SKYRIZI moved closer to funded access for ulcerative colitis. In Korea, reimbursement recalibration strengthened Tagrisso’s advantage over Leclaza … Read more
Pacira has sued WhiteOak and Qilu after ANDA filings for generic EXPAREL, initiating a 30-month FDA stay and strengthening its defense of 21 Orange Book patents.
Neuraxpharm and mjn-neuro will launch EPISERAS, an AI-based earpiece that predicts seizures minutes in advance, offering real-time alerts for patients with drug-resistant epilepsy.
RWE Demonstrates Significant Four-Year MACE Reduction Repatha (Evolocumab), Amgen’s PCSK9 inhibitor, has once again demonstrated its cardiovascular impact, this time in a real-world population exceeding 110,000 patients. New findings presented at the American Heart Association Scientific Sessions 2025 show that the therapy delivers sustained, long-term reductions in major adverse cardiovascular events (MACE) for patients with … Read more
Broader 2026 Coverage Enhances Economics Across Multiple Care Settings A sweeping set of CMS and Medicaid reimbursement decisions is reshaping 2026 access across neuromodulation, electrophysiology, advanced wound reconstruction, diagnostic testing, and regenerative biologics. From APC assignments and ASC approvals to national pricing and expanded Medicaid coverage, these updates strengthen commercial readiness for emerging technologies while … Read more
CMS has issued the CY 2026 ESRD PPS final rule, introducing a higher base rate, new geographic adjustments, revised outlier policies, and changes to the ESRD Quality Incentive Program.
Sotatercept Nears Public Coverage After National Pricing Deal Merck Canada has completed national pricing negotiations with the pan-Canadian Pharmaceutical Alliance (pCPA) for WINREVAIR (sotatercept), marking a significant milestone in the therapy’s journey toward broad public reimbursement across Canada. The agreement, announced on November 20, 2025, positions the first-in-class activin signaling inhibitor one step closer to … Read more
Thailand’s HITAP has established the Global Research Unit to address policy questions that traditional HTA cannot fully answer.
Breaking Down TEVIMBRA Access and the 14-Day Trial Pathway France has taken two decisive steps to reinforce its clinical research ecosystem and expand access to new oncology therapies. The Haute Autorité de Santé (HAS) has issued a favourable reimbursement opinion for TEVIMBRA (tislelizumab) in gastric and oesophageal cancers, while the National Agency for the Safety … Read more